September 22, 2017 9:58 AM ET


Company Overview of Entasis Therapeutics Inc.

Company Overview

Entasis Therapeutics Inc. discovers and develops antibacterials to fight diseases caused by multidrug-resistant bacteria. It offers ETX2514, a broad-spectrum and potent inhibitor of class A, C, and D beta-lactamases that has activity against Acinetobacter baumannii, a gram-negative bacterium that causes severe infections, which are associated with high mortality; ETX0914, a novel oral antibiotic for the treatment of uncomplicated gonorrhea; and a drug discovery platform that focuses on developing novel antibacterials targeting serious gram-negative infections, such as pneumonia, infections of the blood, urinary tract infections, and infections following surgery. The company was founded in 20...

Gatehouse Park BioHub

35 Gatehouse Drive

Building E

Waltham, MA 02451

United States

Founded in 2015



Key Executives for Entasis Therapeutics Inc.

Chief Executive Officer, President and Director
Chief Financial Officer, Chief Business Officer and Director
Age: 51
Chief Medical Officer
Vice President of Projects & Early Development
Chief Scientific Officer
Compensation as of Fiscal Year 2017.

Entasis Therapeutics Inc. Key Developments

Entasis Therapeutics and Global Antibiotic Research & Development Partnership to Develop New Treatment for Drug-Resistant Gonorrhea

Zoliflodacin, a novel oral antibiotic and one of the only treatments in development to address the threat of drug-resistant gonorrhea will enter pivotal trials, due to a new partnership between Global Antibiotic Research and Development Partnership (GARDP) and Entasis Therapeutics. Entasis and GARDP will co-develop the antibiotic, zoliflodacin, in a global Phase 3 clinical trial to be carried out in countries including South Africa, the United States of America, and Thailand. The US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), plans to support pharmacological studies on the drug as part of the development programme. In parallel with the Phase 3 trial, which is sponsored by GARDP/DNDi (Drugs for Neglected Diseases initiative), GARDP will work with Entasis scientists to carry out non-clinical activities – including microbiology surveys to ensure that the product is effective against recent and geographically diverse strains of gonorrhea. If zoliflodacin receives regulatory approval, Entasis will grant GARDP an exclusive license with sublicensing rights in most low- and middle-income countries, while retaining commercial rights in high-income markets. Both GARDP and Entasis are committed to affordable and equitable pricing in their respective territories.

Entasis Therapeutics Inc. Publishes Data Highlighting the Potent and Differentiated Activity of ETX2514 Combinations Against Drug Resistant Gram-Negative Bacteria Including Acinetobacter and Pseudomonas

Entasis Therapeutics Inc. published a report in Nature Microbiology (DOI: 10.1038/nmicrobiol.2017.104) in which Entasis scientists describe the rational design and expanded spectrum activity of ETX2514 against Class A, C, and a broad spectrum of Class D beta-lactamases, important targets in the treatment of resistant bacteria. The report includes the results of in vitro and preclinical in vivo studies, which demonstrate the ability of ETX2514 to restore antimicrobial activity in combination with multiple beta-lactams against Gram-negative, multi-drug resistant (MDR) pathogens. ETX2514 exhibited particularly promising activity in combination with sulbactam against Acinetobacter baumannii, including hard-to-treat carbapenem-resistant and colistin-resistant strains, and with imipenem against carbapenem-resistant Enterobacteriaceae (CRE) and Pseudomonas aeruginosa. The ability of ETX2514 to be administered concurrently with sulbactam and/or imipenem is currently being investigated in a Phase 1 clinical trial.

Entasis Therapeutics Inc. Presents at Jefferies 2017 Global Healthcare Conference, Jun-06-2017 02:00 PM

Entasis Therapeutics Inc. Presents at Jefferies 2017 Global Healthcare Conference, Jun-06-2017 02:00 PM. Venue: Grand Hyatt, 109 E 42nd St, New York, New York, United States. Speakers: Manos Perros, Chief Executive Officer, President and Director.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Tax Management Inc United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Entasis Therapeutics Inc., please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at